Cortalix key facts
- Developer of a biotechnological platform designed for single-domain antibody (sdAb) discovery and development.
- It has raised $1.3M; the latest was Seed Round ($1.0M) in Mar 2025.
- Notable investors include Rabo Investments, Coöperatieve Rabobank., RUG Ventures, Chaperone Pharma, Coöperatieve Rabobank — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch Cortalix: the Monday email on marks, rounds and moves
Cortalix funding rounds
No funding rounds for Cortalix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Cortalix investors
6 investors are on record for Cortalix, including Rabo Investments, Coöperatieve Rabobank., RUG Ventures and Chaperone Pharma.
About Cortalix
Developer of a biotechnological platform designed for single-domain antibody (sdAb) discovery and development. The company's platform offers molecular imaging, targeted therapy, and immunotherapy for research bioanalytical applications, enabling clinicians to efficiently identify patients, target therapy, and monitor disease.
- Sector
- Healthcare
- HQ
- Groningen, Netherlands
- Founded
- 2023
- Employees
- 5
- Website
- cortalix.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Cortalix doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.